US federal regulation
Attorney general says DOJ to address cannabis issues soon…
17th June 2022 - Alerts | North America, United States |
Lawsuit against DEA rule on hemp dismissed…
17th June 2022 - Alerts | North America, United States |
US FDA sends warning letters over CBD animal products…
27th May 2022 - Alerts | North America, United States |
Califf says congressional action needed for CBD…
20th May 2022 - Alerts | North America, United States |
First federal appeals court rules on the legality of delta-8 products…
20th May 2022 - Alerts | North America, United States |
Congressman requests hearing over CBD and delta-8 regulation…
6th May 2022 - Alerts | North America, United States |
US FDA sets its sights on delta-8 THC, firing warnings over health claims
5th May 2022 - Regulatory briefing |
The US Food and Drug Administration (FDA) has sent warning letters to five marketers of delta-8 THC products over health claims made by the companies
DEA defines cannabis seeds with less than 0.3% THC as hemp and as legal
2nd May 2022 - Regulatory briefing |
The US Drug Enforcement Administration (DEA) has confirmed that cannabis seeds fall outside the realm of the Controlled Substances Act (CSA) – regardless of how much THC the plant could eventually yield
Case against DEA interim final hemp rule opens…
20th April 2022 - Alerts | North America, United States |
E-commerce platform Shopify accused of shutting down legal delta-8 THC sales
19th April 2022 - Business briefing |
US-based CBD shops that used Shopify to support online sales are still dealing with the fallout weeks after the e-commerce platform suddenly removed sites it deemed non-compliant
Cannabis seeds are not controlled under federal law…
8th April 2022 - Alerts | North America, United States |
Long trips for a short supply, but there’s optimism in Iowa on medical cannabis
6th April 2022 - Regulatory briefing |
Patients in Iowa who rely on supplies of medical cannabis are tightly restricted in how much they can have, and may face a long trip to get it from one of the few licensed dispensaries in the US state
US FDA warns CBD firms over fraudulent and ‘life-threatening’ Covid claims
5th April 2022 - Regulatory briefing |
The US Food and Drug Administration (FDA) has issued warning letters to seven CBD companies for claiming that some of the products they sell may be used to prevent or cure Covid-19
People vs politics – Wisconsin remains divided over what to do about cannabis
4th April 2022 - Regulatory briefing |
Lawmakers in the US state of Wisconsin are sympathetic to patients who could benefit from medical cannabis – but they don’t want to go against federal law
House passes MORE Act…
4th April 2022 - Alerts | North America, United States |
MORE Act scheduled today for floor vote in US House…
1st April 2022 - Alerts | North America, United States |
FDA sends CBD companies warning letters over Covid health claims….
31st March 2022 - Alerts | North America, United States |
Senate passes Cannabidiol and Marihuana Research Expansion Act…
25th March 2022 - Alerts | North America, United States |
MORE Act up for a House vote once again…
25th March 2022 - Alerts | North America, United States |
Are there lessons for cannabinoids from the new synthetic-nicotine regulation?
24th March 2022 - Blog , Regulatory briefing |
Could the cannabinoid industry learn anything from the recent move to close the loophole that had kept synthetic nicotine out of US Food and Drug Administration oversight?
Omnibus bill urges FDA to regulate CBD…
14th March 2022 - Alerts | North America, United States |
USDA requests another hemp survey…
28th February 2022 - Alerts | North America, United States |
It’s not NORML: cannabis advocates warn against ‘illegal and unproven’ intoxicants
23rd February 2022 - Business briefing |
One of the oldest surviving and best known advocacy organisations for cannabis legalisation has come out strongly against hemp-derived intoxicating cannabinoids such as delta-8 THC
Cannabis payments for injured workers?
23rd February 2022 - Alerts | United States |
Senate confirms Califf appointment…
16th February 2022 - Alerts | United States |
Intoxicating but legal? Expert views differ as US firms take the risk on delta-9 THC
1st February 2022 - Business briefing |
Hemp companies are creating new products marketed to get the user high legally in all 50 US states. Industry experts disagree on whether these companies are risk-taking pioneers, or simply shortsighted
US lawsuits end DEA restrictions on sources of cannabis for researchers
26th January 2022 - Regulatory briefing |
Lawsuits in the US have finally overturned the DEA’s requirement that researchers interested in studying cannabis could only purchase from one source, the University of Mississippi
More of the same in US 2022 – expect state moves and federal stalemate
17th January 2022 - Regulatory briefing |
Last year saw no movement on cannabinoid issues at federal level in the US, as CBD-Intel predicted, and it’s not looking too good for this year either – though we anticipate some continued movement at state level
How US Democrats’ cannabis reform plans ran aground despite promises
12th January 2022 - Blog , Regulatory briefing |
After early promise, no cannabis-focused legislation has yet made it onto president Joe Biden’s desk for signing. So why is that?
Rival bills aim to establish a pathway to the US market for ingestible CBD
3rd January 2022 - Regulatory briefing |
US representatives have introduced a bill into the House aiming to push the US Food and Drug Administration (FDA) to regulate CBD in food and drinks
CBD-Intel’s crystal ball reveals possible intoxicating prospects for the year ahead
29th December 2021 - Business briefing |
“Intoxicating” will be the word to watch for and THC will be the main driver for developments in 2022, CBD-Intel predicts
How well did we do? CBD-Intel’s predictions for 2021 reviewed
28th December 2021 - Business briefing |
CBD-Intel was on point in its 2021 predictions. Much like the preceding year, we believed 2021 would largely be defined more by what did not happen than what did
So it’s farewell to 2021 – a year that promised little and delivered less
27th December 2021 - Business briefing |
If 2020 was the year in the waiting-room then 2021 was perhaps the year of the unfulfilled hype. As predicted, there was little movement in many of the major issues controlling the CBD market
Legal eagle Kight explains how the USPS could have modified PACT Act regulation
22nd December 2021 - Blog , Regulatory briefing |
Does the United States Postal Service (USPS) really have the authority to permit the shipping of CBD vaping products under the PACT Act?
Intoxicating hemp products in the US – opportunity or risk?
20th December 2021 - Regulatory reports |
Some sellers of intoxicating cannabinoid products claim legality under the 2018 US Farm Bill. CBD-Intel believes that many hemp-derived cannabinoids do not violate federal controlled substance law
Republican bill could create ingestible CBD pathway, but passage remains iffy
26th November 2021 - Regulatory briefing |
Nancy Mace, a first-term Republican Congresswoman from South Carolina, recently introduced a bill in the House of Representatives that would decriminalise cannabis at the federal level
Gupta’s appointment and nomination of Califf may indicate change in US climate
16th November 2021 - Regulatory briefing |
Rahul Gupta has been confirmed by the US Senate as director of National Drug Control Policy, while president Joe Biden intends to nominate Robert Califf as head of the US Food and Drug Administration (FDA)
Couche-Tard tipped for a big future in US CBD retail through its Circle K stores
11th November 2021 - Business briefing |
It owns one of North America’s biggest chains of convenience stores and fuel stations – now Alimentation Couche-Tard may have the potential to become one of its foremost providers of cannabis and CBD
Charlotte’s Web new dietary ingredient application did include ValidCare data
14th October 2021 - Blog , Business briefing |
It turns out the Charlotte’s Web application to the US FDA for the registration of a full spectrum hemp extract as a new dietary ingredient (NDI) DID include data from the ValidCare industry study
Is CBD a dietary ingredient or a drug? US FDA ‘appears to have changed its mind’
13th October 2021 - Regulatory briefing |
The lack of a clear regulatory pathway to market for CBD products in the US is highlighted by a row over the FDA’s denial of new dietary ingredient (NDI) approval for full spectrum hemp extracts
Could CBD companies face scrutiny from another US regulatory agency?
6th October 2021 - Blog , Regulatory briefing |
Does the CBD industry now face increased scrutiny from the US Securities and Exchange Commission (SEC)?
Gloomy US outlook for CBD production as regulatory uncertainty strangles farms
30th September 2021 - Business briefing |
A lack of regulatory clarity is the primary reason behind a predicted dramatic fall in hemp acreage dedicated to the production of CBD in the US
FDA warning flags up delta-8 THC as the likely next target for US enforcement
16th September 2021 - Regulatory briefing |
Enforcement action against companies pushing the limits on marketing delta-8 THC products in the US is likely following a health advisory from the FDA and CDC
FDA and CDC warnings won’t signal the end of the delta-8 THC market in the US
16th September 2021 - Blog , Regulatory briefing |
The US Food and Drug Administration (FDA) and Centers for Disease Control (CDC) have issued warnings about the rise of reported incidents in the US regarding the use of delta-8 THC
No Joy: USPTO confirms no trademarks are allowed for ‘illegal’ CBD products
14th September 2021 - Regulatory briefing |
CBD products are not eligible for trademark protection, US regulators have reaffirmed, because they are not legal under the federal Food, Drug, and Cosmetic Act (FDCA)
Delta-8 THC regulation in the US
13th September 2021 - Presentations , Resources |
What is delta-8 THC and how does US law deal with it, at both federal and state level? In this presentation, CBD-Intel legal analyst Anthony Traurig shares his insights
Horse sense or dog trial? The science and law behind CBD petcare products
1st September 2021 - Business briefing |
CBD pet products remain in a grey area in terms of both legality and effectiveness – but there have been some attempts in both to shed light into the darkness
What conclusions can be drawn from the FDA rejection of full hemp extracts as supplements?
18th August 2021 - Blog , Regulatory briefing |
The FDA recently rejected applications from both Charlotte’s Web and Irwin Naturals to use a hemp extract as a dietary supplement
Could e-cig ‘shake and vape’ be a model for sales of ingestible CBD products?
5th August 2021 - Blog , Regulatory briefing |
There remains no certainty over the future regulation of ingestible CBD products in many jurisdictions